Is KALV or ORKA more profitable?

Oruka Therapeutics' return on equity of -26.16% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Oruka Therapeutics N/A -26.16% -25.00%

Is KALV or MANE more profitable?

Veradermics' return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Veradermics N/A N/A N/A

KalVista Pharmaceuticals (KALV) Competitors

$27.00 0.00 (0.00%)

As of 06/12/2026

Compare

KALV vs. AMRX, TVTX, ORKA, LEGN, and MANE

Should you buy KalVista Pharmaceuticals stock or one of its competitors? MarketBeat compares KalVista Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KalVista Pharmaceuticals include Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), Legend Biotech (LEGN), and Veradermics (MANE). These companies are all part of the "pharmaceutical products" industry.

How does KalVista Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 2 mentions for Amneal Pharmaceuticals and 0 mentions for KalVista Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.12 beat KalVista Pharmaceuticals' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
KalVista Pharmaceuticals	Neutral

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to KalVista Pharmaceuticals' net margin of 0.00%. Amneal Pharmaceuticals' return on equity of -313.96% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Amneal Pharmaceuticals presently has a consensus target price of $15.80, indicating a potential downside of 7.87%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given KalVista Pharmaceuticals' higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Amneal Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.80	$72.06M	$0.38	45.13
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Summary

Amneal Pharmaceuticals beats KalVista Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Travere Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

KalVista Pharmaceuticals has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Travere Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. Travere Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.78	-$25.55M	-$0.23	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Travere Therapeutics presently has a consensus price target of $52.08, indicating a potential downside of 8.47%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 13.33%. Given KalVista Pharmaceuticals' higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Travere Therapeutics had 6 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 6 mentions for Travere Therapeutics and 0 mentions for KalVista Pharmaceuticals. Travere Therapeutics' average media sentiment score of 1.31 beat KalVista Pharmaceuticals' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Travere Therapeutics	Positive
KalVista Pharmaceuticals	Neutral

Summary

Travere Therapeutics beats KalVista Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Oruka Therapeutics?

KalVista Pharmaceuticals (NASDAQ:KALV) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Oruka Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 2 mentions for Oruka Therapeutics and 0 mentions for KalVista Pharmaceuticals. Oruka Therapeutics' average media sentiment score of 0.25 beat KalVista Pharmaceuticals' score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
KalVista Pharmaceuticals	Neutral
Oruka Therapeutics	Neutral

KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market.

Oruka Therapeutics' return on equity of -26.16% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Oruka Therapeutics	N/A	-26.16%	-25.00%

KalVista Pharmaceuticals currently has a consensus price target of $30.60, indicating a potential upside of 13.33%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 57.61%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

56.4% of Oruka Therapeutics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oruka Therapeutics has lower revenue, but higher earnings than KalVista Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Oruka Therapeutics beats KalVista Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

KalVista Pharmaceuticals has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Legend Biotech has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

KalVista Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.40	-$296.80M	-$0.68	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

In the previous week, Legend Biotech had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 2 mentions for Legend Biotech and 0 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.00 beat Legend Biotech's score of -0.07 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Legend Biotech	Neutral
KalVista Pharmaceuticals	Neutral

Legend Biotech presently has a consensus target price of $60.23, indicating a potential upside of 101.37%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Legend Biotech is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Legend Biotech beats KalVista Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Veradermics?

KalVista Pharmaceuticals (NASDAQ:KALV) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, KalVista Pharmaceuticals' average media sentiment score of 0.00 equaled Veradermics'average media sentiment score.

Company	Overall Sentiment
KalVista Pharmaceuticals	Neutral
Veradermics	Neutral

Veradermics has lower revenue, but higher earnings than KalVista Pharmaceuticals. Veradermics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Veradermics' return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Veradermics	N/A	N/A	N/A

KalVista Pharmaceuticals presently has a consensus price target of $30.60, indicating a potential upside of 13.33%. Veradermics has a consensus price target of $114.20, indicating a potential downside of 12.06%. Given KalVista Pharmaceuticals' higher probable upside, equities analysts clearly believe KalVista Pharmaceuticals is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Veradermics beats KalVista Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get KalVista Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALV vs. The Competition

Export

Metric	KalVista Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.44B	$3.10B	$7.18B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.51%
P/E Ratio	-7.80	20.06	28.02	24.70
Price / Sales	1,008.07	357.03	535.36	97.93
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	9.96	4.32	10.96	6.46
Net Income	-$109.52M	$64.45M	$3.57B	$337.01M
7 Day Performance	N/A	2.97%	2.12%	1.69%
1 Month Performance	0.19%	6.83%	5.25%	3.81%
1 Year Performance	126.89%	29.07%	33.29%	23.90%

KalVista Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALV KalVista Pharmaceuticals	2.2534 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100
AMRX Amneal Pharmaceuticals	2.0412 of 5 stars	$17.29 +0.3%	$15.80 -8.6%	+100.4%	$5.50B	$3.02B	45.50	8,500
TVTX Travere Therapeutics	1.9143 of 5 stars	$58.30 -0.9%	$52.08 -10.7%	+279.3%	$5.47B	$536.20M	N/A	460	News Coverage Positive News
ORKA Oruka Therapeutics	3.1357 of 5 stars	$92.49 +2.1%	$131.30 +42.0%	+576.5%	$5.46B	N/A	N/A	N/A	Analyst Downgrade Gap Up
LEGN Legend Biotech	3.1043 of 5 stars	$29.39 +2.4%	$60.23 +104.9%	-15.4%	$5.33B	$1.14B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALV) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. AMRX, TVTX, ORKA, LEGN, and MANE

How does KalVista Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does KalVista Pharmaceuticals compare to Travere Therapeutics?

Summary

How does KalVista Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does KalVista Pharmaceuticals compare to Legend Biotech?

Summary

How does KalVista Pharmaceuticals compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. AMRX, TVTX, ORKA, LEGN, and MANE

How does KalVista Pharmaceuticals compare to Amneal Pharmaceuticals?

Do institutionals & insiders believe in AMRX or KALV?

Does the media favor AMRX or KALV?

Which has more risk and volatility, AMRX or KALV?

Is AMRX or KALV more profitable?

Do analysts recommend AMRX or KALV?

Which has preferable earnings and valuation, AMRX or KALV?

Summary

How does KalVista Pharmaceuticals compare to Travere Therapeutics?

Which has more risk & volatility, TVTX or KALV?

Is TVTX or KALV more profitable?

Which has better earnings and valuation, TVTX or KALV?

Do analysts rate TVTX or KALV?

Does the media favor TVTX or KALV?

Summary

How does KalVista Pharmaceuticals compare to Oruka Therapeutics?

Does the media prefer KALV or ORKA?

Which has more risk & volatility, KALV or ORKA?

Is KALV or ORKA more profitable?

Do analysts prefer KALV or ORKA?

Do insiders and institutionals believe in KALV or ORKA?

Which has higher valuation & earnings, KALV or ORKA?

Summary

How does KalVista Pharmaceuticals compare to Legend Biotech?

Is LEGN or KALV more profitable?

Which has more risk and volatility, LEGN or KALV?

Do insiders & institutionals have more ownership in LEGN or KALV?

Which has preferable earnings and valuation, LEGN or KALV?

Does the media favor LEGN or KALV?

Do analysts prefer LEGN or KALV?

Summary

How does KalVista Pharmaceuticals compare to Veradermics?

Does the media favor KALV or MANE?

Which has preferable valuation & earnings, KALV or MANE?

Is KALV or MANE more profitable?

Do analysts recommend KALV or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools